Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

ClinicalTrials.gov ID: NCT01001923

Public ClinicalTrials.gov record NCT01001923. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of SAR164877 (REGN475) on Reduction of Pain From Chronic Pancreatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary objective was to demonstrate the activity of REGN475/SAR164877 in reducing the pain associated with chronic pancreatitis. Secondary objectives were: * to assess the safety and tolerability of REGN475/SAR164877 in patients with chronic pancreatitis pain; * to characterize the pharmacokinetic, pharmacodynamic, and immunogenicity profiles of REGN475/SAR164877 in this population; * to measure the change in the total daily dose of rescue medications required.

Study identification

NCT ID
NCT01001923
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
15 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2009
Primary completion
Dec 31, 2010
Completion
Dec 31, 2010
Last update posted
May 26, 2013

2009 – 2011

United States locations

U.S. sites
17
U.S. states
10
U.S. cities
17
Facility City State ZIP Site status
Sanofi-Aventis Investigational Site Number 840024 Arcadia California 91007
Sanofi-Aventis Investigational Site Number 840011 Bell Gardens California 90201
Sanofi-Aventis Investigational Site Number 840003 Monterey California 93940
Sanofi-Aventis Investigational Site Number 840048 San Diego California 92103
Sanofi-Aventis Investigational Site Number 840034 Stanford California 94305
Sanofi-Aventis Investigational Site Number 840031 Miami Florida 33144
Sanofi-Aventis Investigational Site Number 840029 St. Petersburg Florida 33703
Sanofi-Aventis Investigational Site Number 840017 Marietta Georgia 30060
Sanofi-Aventis Investigational Site Number 840013 Worcester Massachusetts 01655
Sanofi-Aventis Investigational Site Number 840030 Lebanon New Hampshire 03756
Sanofi-Aventis Investigational Site Number 840023 New York New York 10016
Sanofi-Aventis Investigational Site Number 840052 Winston-Salem North Carolina 27103
Sanofi-Aventis Investigational Site Number 840005 Cleveland Ohio 44195
Sanofi-Aventis Investigational Site Number 840043 Dallas Texas 75204
Sanofi-Aventis Investigational Site Number 840053 DeSoto Texas 75115
Sanofi-Aventis Investigational Site Number 840050 Southlake Texas 76092
Sanofi-Aventis Investigational Site Number 840040 East Sandy Utah 84094

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01001923, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 26, 2013 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01001923 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →